ostarine

Ostarine, also known as enobosarm and sold under the code MK-2866, is a selective androgen receptor modulator (SARM) developed to treat muscle wasting and related conditions. It is a non-steroidal compound designed to act on androgen receptors with tissue-selective effects, aiming to stimulate muscle and bone while reducing androgenic effects in other tissues.

As a SARM, ostarine binds to androgen receptors and modulates receptor activity in a way that can promote protein synthesis and lean mass in muscle tissue. This tissue selectivity is one reason it has been investigated for conditions such as cancer cachexia and osteoporosis. It is not approved as a medical treatment and is not available as a legitimate prescription drug.

In clinical research, ostarine has shown dose-dependent gains in lean body mass and, in some studies, improvements in physical function in patients with cachexia or muscle-wasting conditions. However, results have been mixed and not all trials demonstrated meaningful clinical benefit. Safety data from trials indicate potential testosterone suppression and changes in lipid parameters, with some reports of elevated liver enzymes; long-term safety remains uncertain.

Regulatory status is that ostarine is not approved by major health authorities for any indication. It is banned by the World Anti-Doping Agency for athletes. In the consumer market, it is sometimes sold as a research chemical, and products marketed as dietary supplements may be illicit or adulterated. As with other SARMs, its use carries potential health risks and legal uncertainties.